Colorectal Adenocarcinoma

About
Mappings

OncoTree: Colorectal Adenocarcinoma (oncotree:COADREAD)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan FDA
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan FDA
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab FDA
Sensitivity (+) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib FDA
Sensitivity (+) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib FDA
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Ipilimumab, Nivolumab FDA
Sensitivity (+) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab FDA
Sensitivity (+) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab FDA
Sensitivity (+) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Panitumumab FDA
Sensitivity (+) dMMR Colorectal Adenocarcinoma Pembrolizumab FDA
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Pembrolizumab FDA
Sensitivity (+) HER2-positive, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Trastuzumab, Tucatinib FDA
Sensitivity (+) KRAS p.G12C Colorectal Adenocarcinoma Adagrasib, Cetuximab FDA
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Nivolumab FDA
Sensitivity (+) dMMR Colorectal Adenocarcinoma Nivolumab FDA
Sensitivity (+) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin FDA
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Ipilimumab, Nivolumab FDA
Sensitivity (+) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab FDA
Sensitivity (+) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib HC
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan HC
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan HC
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab HC
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab HC
Sensitivity (+) dMMR Colorectal Adenocarcinoma Pembrolizumab HC
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Pembrolizumab HC
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Panitumumab HC